What is Tempest Therapeutics's market cap?

Tempest Therapeutics (TPST) has a market capitalization of $14.9M and trades on NASDAQ.

Who are Tempest Therapeutics's competitors?

Tempest Therapeutics's key competitors include Bristol-Myers Squibb, CytomX Therapeutics, Inc., TScan Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Tempest Therapeutics partner with?

Tempest Therapeutics's notable partners include National Cancer Institute, Cancer Prevention Clinical Trials Network.

Where is Tempest Therapeutics headquartered?

Tempest Therapeutics is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2021.

Tempest Therapeutics

TPST

Tempest Therapeutics is a clinical-stage biotechnology company focused on developing a diversified portfolio of cell therapies and small molecule product candidates.

Market cap

$14.93M-46.2%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

EPS-$0.51Miss by $0.23

Read the full report

Next report

Aug 10, 2026 (In 1 week)

EPS estimate-$0.30

Competitors

By market cap

Bristol-Myers Squibb$127.75B+32.1%

CytomX Therapeutics$707.5M+87.9%

Allogene Therapeutics$604.0M+87.9%

Lyell Immunopharma, Inc.$317.6M+24.5%

Cartesian Therapeutics, Inc.$228.9M-35.6%

Caribou Biosciences, Inc.$157.7M-26.0%

TScan Therapeutics, Inc.$50.2M-52.6%

Tempest Therapeutics$14.9M-49.8%

By revenue growth

Bristol-Myers Squibb+1.8%

CytomX Therapeutics-75.9%

By net margin

Bristol-Myers Squibb15.01%+3.8pp

CytomX Therapeutics-166.4%-195pp

Allogene Therapeutics-1,170,863.64%—

Profile

Tempest Therapeutics is a clinical-stage biotechnology company focused on developing a diversified portfolio of cell therapies and small molecule product candidates. The company aims to address high unmet medical needs in oncology and immunology by advancing targeted therapies through clinical development. Their value proposition centers on dual-targeting CAR-T technologies and specialized small molecule inhibitors for specific cancer indications.

Competitive position

A clinical-stage innovator leveraging a dual-modality approach combining CAR-T cell therapies with small molecule inhibitors.

GeographiesUnited States

Customer segmentsHealthcare providers, Pharmaceutical companies, Clinical trial networks

Business modelR&D intensive, Licensing and royalties, Clinical-stage drug development

SuppliersSpecialized contract manufacturing organizations, Raw material suppliers for cell therapy, Academic research institutions

CustomersHospitals, Specialty pharmacies, Large pharmaceutical partners for commercialization

CountryUnited States of America

Listed2021

Employees17.0

CEOMatthew Angel

SectorHealthcare

IndustryBiotechnology

Websitetempesttx.com

FilingsSEC EDGAR

Questions, answered.

What is Tempest Therapeutics's market cap?: Tempest Therapeutics (TPST) has a market capitalization of $14.9M and trades on NASDAQ.
Who are Tempest Therapeutics's competitors?: Tempest Therapeutics's key competitors include Bristol-Myers Squibb, CytomX Therapeutics, Inc., TScan Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Tempest Therapeutics partner with?: Tempest Therapeutics's notable partners include National Cancer Institute, Cancer Prevention Clinical Trials Network.
Where is Tempest Therapeutics headquartered?: Tempest Therapeutics is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2021.